Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
0
Authors
Volker Heinemann
31 more
Volker Heinemann
•
Ludwig Weikersthal
29 more
•
Sebastian Stintzing
Published
July 31, 2014
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Medicine
Cancer Oncology
Internal Medicine
Hepatology
Pulmonary And Respiratory Medicine
Show all topics
DOI
10.1016/s1470-2045(14)70330-4
